Erich Spangenberg has been appointed chief executive officer of Dallas-based Spectral AI Inc.’s IP-focused subsidiary, Spectral IP.

Spectral AI is an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care.

According to Spectral AI CEO Pete Carlson, Spangenberg is the company’s largest shareholder and has an “unrivaled track record in global IP investment, monetization, enforcement, acquisition, and licensing.”

Carlson announced that Spectral AI aims to create a healthcare IP-focused enterprise through Spectral IP, with a goal to provide additional IP protection for the company and unlock “additional value for MDAI shareholders while requiring limited company management resources and no additional capital from the Company.”

As CEO of Spectral IP, Spangenberg will report to Carlson and the Board as he prepares the subsidiary for a potential spin-off.

1,000+ IP licensing transactions

Spangenberg is the founder and co-managing partner at Sauvegarder Investment Management (SIM), a multi-strategy investment firm dedicated to IP-related financing and investment opportunities. SIM invests across IP as an asset class and across jurisdictions, primarily focusing on the US, Europe, and Asia.

He is recognized by various publications as one of the world’s top-50 IP strategists, credited with being one of the people who is changing the way people think about and use patents.

In a statement, Spangenberg expressed optimism about the subsidiary’s prospects.”I believe Spectral IP represents a significant opportunity to deliver additional value to Spectral AI shareholders,” he said. Highlighting financial strategies, Spangenberg added, “One of my affiliates has provided Spectral IP with $1.0 million of debt capital. I believe I can secure an additional $5.0-$10.0 million of equity capital for our new entity, which I believe will be more than adequate to fund Spectral IP for approximately one year after a possible spin-off transaction is completed.”

He further outlined his plans, “As the largest shareholder and investor in Spectral AI, I plan to utilize my global network and my decades of IP experience to focus on healthcare IP-related investments and acquisitions. These IP-related investments and acquisitions will include licensing, sales, royalty finance, credit-related and other diverse financial opportunities within the IP class.”

After an early career that included partnership in a leading global law firm, investment banker, and business executive, in 2003, Spangenberg focused his business efforts on IP investment opportunities.

He has been involved as a principal in over 1,000 IP licensing transactions that generated over $500 million in revenue and as a principal and advisor on over $2 billion of patent financing and technology acquisition transactions.

A potential spin-off and Spectral AI’s DeepView

Spectral AI also announced that a special committee of the board of directors will be formed to evaluate and oversee the implementation of the contemplated transactions, including a possible partial spin-off transaction of Spectral IP shares to its shareholders.

A predictive AI company, Spectral AI is focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers.

The company is working to revolutionize the management of wound care by “Seeing the Unknown” with its DeepView System, a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.